Analysis Date: 2026-04-27
Sector: Healthcare
Industry: Biotechnology
Exchange: NYSE

Executive Summary

Veradermics, Incorporated ($MANE) is currently trading at $92.28 (🟢 +36.03% today) with a market capitalization of $3.45B.

Veradermics, Incorporated operates as a biopharmaceutical company focused on developing novel therapeutics for dermatologic and aesthetic conditions. The company develops treatments for Pattern Hair Loss affecting adults and children. The company's products include VDPHL01, an oral, non-hormonal treatment for men and women with PHL for chronic hair loss therapy.

Price & Valuation

Current Price: $92.28 (at 1:05 PM ET)
Current Volume: 2.4M
Day Range: $73.40 - $101.81
52-Week Range: $32.00 - $101.81
P/E Ratio: -701.42

DCF Valuation: Overvalued

• Intrinsic Value (Unlevered DCF): $0.26
• Current Price: $92.28
• Discount/Premium: -99.7%

Levered DCF: $0.26 (-99.7%)

DCF analysis suggests the stock may be trading at a 99.7% premium to its intrinsic value.

DCF values calculated as of 2026-04-27. Underlying assumptions are not disclosed by the data provider. Levered vs unlevered can diverge materially for highly levered companies.

Market Context

Major Indices:

• S&P 500: $7166.38 (🟢 +0.02%)
• NASDAQ Composite: $24829.25 (🔴 -0.03%)
• Dow Jones Industrial Average: $49160.65 (🔴 -0.14%)

Peer Comparison

Peer comparison (11 companies):

• MANE - Veradermics, Incorporated ($92.28, +36.0%, $3.45B) ← Current
• TVTX - Travere Therapeutics, Inc. ($41.06, +1.4%, $3.79B)
• OVID - Ovid Therapeutics Inc. ($2.63, +1.0%, $346M)
• ABEO - Abeona Therapeutics Inc. ($5.38, -0.1%, $307M)
• HELP - Cybin Inc. Common Stock ($5.61, +0.0%, $280M)
• PLYX - Polaryx Therapeutics, Inc. Common Stock ($4.93, +1.6%, $233M)
• THAR - Tharimmune, Inc. ($3.54, +6.6%, $140M)
• LSTA - Lisata Therapeutics, Inc. ($3.10, -3.1%, $28M)
• ADIL - Adial Pharmaceuticals, Inc. ($1.57, -0.3%, $2M)
• DRMA - Dermata Therapeutics, Inc. ($1.25, +0.4%)
• XTLB - XTL Biopharmaceuticals Ltd. ($2.43, +2.7%)

Financial Performance

Latest Quarter (2024-12-31):

• Revenue: $0.00M
• Net Income: $-5.66M
• EPS: $-0.03

Earnings Calendar

Next Earnings Report: 2026-06-03 (During Trading Day)

• EPS Estimate: $-0.65

2 upcoming earnings dates tracked

Most Recent Report: 2026-03-30

• EPS: $-1.06 (Est: $-1.81) ✓ Beat

Historical Data: 4 earnings events tracked

Analyst Outlook

Analyst Price Target Consensus:

• Target: $75.00 (-18.7% upside)
• Range: $75.00 - $75.00
• Median: $75.00

Next Quarter Estimates (2027-12-31):

• EPS: $-1.02

Analyst Consensus

Overall Rating: Buy

Rating Distribution (1 total ratings):

• 🟢 Buy/Outperform: 1 (100.0%)
• ⚪ Hold/Neutral: 0 (0.0%)
• 🔴 Sell/Underperform: 0 (0.0%)

Recent Analyst Actions:

• Citigroup (2026-03-02): Initiate Buy
• Cantor Fitzgerald (2026-03-02): Initiate Overweight
• Jefferies (2026-03-02): Initiate Buy

Consensus based on 1 analyst ratings from major financial institutions

Trading Signals

👉 Our technical analysis identified 1 trading signal(s) in the last 60 days:

• 2026-04-13: Momentum Swing - breakout @ $71.36

News Sentiment Analysis

AI Analysis (based on 20 recent articles):

Recent headlines highlight Veradermics' positive Phase 2/3 trial results for VDPHL01, showing robust hair growth and driving a 25% stock surge. Analysts rate it 'Moderate Buy' with high price targets, and the company completed a successful upsized IPO with insider buying. Sentiment is overwhelmingly positive due to clinical successes and market enthusiasm.

Key Themes:

• Positive clinical trial results
• Analyst buy ratings and stock gains
• Successful IPO and corporate milestones

Sentiment: Positive (95% confidence)

Recent News

5 most recent articles covering MANE:

• Newly Listed Veradermics Hair Loss Drug Shows Hair Growth Gains (benzinga.com, 2026-04-27) — Read more
• How This Biotech, Up 25%, Is Taking A Page Out Of Rogaine's Playbook (investors.com, 2026-04-27) — Read more
• Veradermics' Oral VDPHL01 Achieved Early, Consistent, and Robust Hair Growth in Positive Phase 2/3 ‘302' Clinical Trial in Male Pattern Hair Loss (businesswire.com, 2026-04-27) — Read more
• Veradermics to Hold Conference Call to Discuss Topline Results from Phase 2/3 ‘302' Study of VDPHL01 in Males with Mild-to-Moderate Pattern Hair Loss (businesswire.com, 2026-04-26) — Read more
• MANE (NYSE:MANE) Receives Average Rating of “Moderate Buy” from Analysts (defenseworld.net, 2026-04-24) — Read more

Full news analysis based on 20 recent articles

👉 Disclaimer: This is not investment advice. Always do your own research before making investment decisions.